Also read: The pandemic push to the silver economyThe companies said that none of their systems had been breached in connection with the incident and that they are “unaware that any study participants have been identified through the data being accessed."Pfizer and BioNTech said the EMA informed them that the attack would have no effect on the timing of the vaccine review.
Regulators are already evaluating clinical trial data on a rolling basis, and a clearance is expected toward the end of the year.Pfizer shares closed on Wednesday down 1.7% to $41.85 in New York.The EMA issued a brief statement Wednesday saying that it had been attacked and had “swiftly launched a full investigation, in close cooperation with law enforcement and other.